Sources & References
Authoritative clinical data backing our educational content.
Retatrutide Club relies on primary literature and peer-reviewed journals. Below is a selected bibliography of foundational studies informing our content.
Primary Clinical Trials (Phase 2)
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
The Lancet. Published: June 26, 2023. - Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.
The New England Journal of Medicine (NEJM). Published: June 26, 2023.
Pharmacology and Mechanisms
- LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
The Lancet. 2022. - The role of glucagon in energy expenditure and hepatic lipid metabolism.
Various systemic reviews detailing the independent effects of GCGR agonism.
Ongoing Research (Phase 3 TRIUMPH)
Information regarding the Phase 3 TRIUMPH clinical trial program is sourced directly from clinical registry databases (e.g., ClinicalTrials.gov) under the identifier prefixes for the respective TRIUMPH 1-4 studies.